Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Decrease in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 17,574 shares, a drop of 48.6% from the October 15th total of 34,177 shares. Based on an average daily volume of 16,714 shares, the short-interest ratio is currently 1.1 days. Approximately 0.4% of the company’s stock are sold short.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently raised its stake in Alzamend Neuro stock. Kingsbury Capital Investment Advisors LLC lifted its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 134.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,329,100 shares of the company’s stock after buying an additional 762,367 shares during the quarter. Alzamend Neuro comprises 1.3% of Kingsbury Capital Investment Advisors LLC’s portfolio, making the stock its 18th biggest holding. Kingsbury Capital Investment Advisors LLC owned 27.75% of Alzamend Neuro worth $1,595,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Stock Performance

Shares of ALZN stock opened at $1.24 on Monday. Alzamend Neuro has a 12 month low of $0.84 and a 12 month high of $2.56. The stock has a market cap of $5.98 million, a P/E ratio of -0.54 and a beta of 0.41. The company has a 50 day simple moving average of $1.48 and a two-hundred day simple moving average of $1.44.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last issued its quarterly earnings results on Thursday, September 10th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.12). As a group, equities analysts forecast that Alzamend Neuro will post -1.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.00.

Read Our Latest Research Report on Alzamend Neuro

Alzamend Neuro Company Profile

(Get Free Report)

Alzamend Neuro is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease and other neuropsychiatric disorders. The company is based in the United States and does not have marketed products. Its pipeline includes AL001, an investigational lithium-based treatment being studied for conditions including Alzheimer’s disease and bipolar disorder, and ALZN002, an investigational cell-based immunotherapy designed to target Alzheimer’s disease. Both programs remain in development, and their safety and effectiveness have not been established.

Featured Articles

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.